Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapyDRUKER, Brian J.European journal of cancer. Supplement (1990). 2002, Vol 38, Num 5, pp S70-S76, issn 1359-6349Conference Paper

Sceptical scientistsDRUKER, Brian J.Lancet (British edition). 2001, Vol 358, Num DEC, issn 0140-6736, p. s11, SUPArticle

Translation of the Philadelphia chromosome into therapy for CMLDRUKER, Brian J.Blood. 2008, Vol 112, Num 13, pp 4808-4817, issn 0006-4971, 10 p.Article

Imatinib alone and in combination for chronic myeloid leukemiaDRUKER, Brian J.Seminars in hematology. 2003, Vol 40, Num 1, pp 50-58, issn 0037-1963, 9 p.Article

Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CMLDRUKER, Brian J.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8541-8546, issn 0950-9232, 6 p.Article

Chronic myeloid leukemia : current treatment optionsGOLDMAN, John M; DRUKER, Brian J.Blood. 2001, Vol 98, Num 7, pp 2039-2042, issn 0006-4971Article

The development of imatinib as a therapeutic agent for chronic myeloid leukemiaDEININGER, Michael; BUCHDUNGER, Elisabeth; DRUKER, Brian J et al.Blood. 2005, Vol 105, Num 7, pp 2640-2653, issn 0006-4971, 14 p.Article

Inhibition of the Bcr-abl tyrosine kinase as a therapeutic strategy for CMLDRUKER, Brian J.Oncogene (Basingstoke). 2002, Vol 21, Num 56, pp 8541-8546, issn 0950-9232, 6 p., NS7Article

Chronic myelogenous leukaemia - new therapeutic principlesO'DWYER, Michael E; DRUKER, Brian J.Journal of internal medicine. 2001, Vol 250, Num 1, pp 3-9, issn 0954-6820Article

Philadelphia chromosome-positive leukemias: From basic mechanisms to molecular therapeuticsKURZROCK, Razelle; KANTARJIAN, Hagop M; DRUKER, Brian J et al.Annals of internal medicine. 2003, Vol 138, Num 10, pp 819-830, issn 0003-4819, 12 p.Article

StI571 as a targeted therapy for CMLO'DWYER, Michael E; MAURO, Michael J; DRUKER, Brian J et al.Cancer investigation. 2003, Vol 21, Num 3, pp 429-438, issn 0735-7907, 10 p.Article

Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cellsTHIESING, J. Tyler; OHNO-JONES, Sayuri; KOLIBABA, Kathryn S et al.Blood. 2000, Vol 96, Num 9, pp 3195-3199, issn 0006-4971Article

Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive LeukemiaO'HARE, Thomas; DEININGER, Michael W. N; EIDE, Christopher A et al.Clinical cancer research (Print). 2011, Vol 17, Num 2, pp 212-221, issn 1078-0432, 10 p.Article

Ocular side-effects associated with imatinib mesylate (Gleevec®)FRAUNFELDER, Frederick W; SOLOMON, Jonathan; DRUKER, Brian J et al.Journal of ocular pharmacology and therapeutics. 2003, Vol 19, Num 4, pp 371-375, issn 1080-7683, 5 p.Article

Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignanciesHEINRICH, Michael C; BLANKE, Charles D; DRUKER, Brian J et al.Journal of clinical oncology. 2002, Vol 20, Num 6, pp 1692-1703, issn 0732-183XArticle

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinibCORBIN, Amie S; LA ROSEE, Paul; STOFFREGEN, Eric P et al.Blood. 2003, Vol 101, Num 11, pp 4611-4614, issn 0006-4971, 4 p.Article

Practical management of patients with chronic myeloid leukemia receiving imatinibDEININGER, Michael W. N; O'BRIEN, Stephen G; FORD, John M et al.Journal of clinical oncology. 2003, Vol 21, Num 8, pp 1637-1647, issn 0732-183X, 11 p.Article

Chronic myeloid leukemia in the imatinib eraDRUKER, Brian J.Seminars in hematology. 2003, Vol 40, Num 2, pp 1-3, issn 0037-1963, 3 p., SUP2Conference Paper

STI571: A paradigm of new agents for cancer therapeuticsMAURO, Michael J; O'DWYER, Michael; HEINRICH, Michael C et al.Journal of clinical oncology. 2002, Vol 20, Num 1, pp 325-334, issn 0732-183XArticle

Mice lacking the homologue of the human 22q11.2 gene CRKL phenocopy neurocristopathies of DiGeorge syndromeGURIS, Deborah L; FANTES, Judith; TARA, David et al.Nature genetics. 2001, Vol 27, Num 3, pp 293-298, issn 1061-4036Article

Imatinib. CommentariesLYSENG-WILLIAMSON, Katherine; JARVIS, Blair; GOLDMAN, John M et al.Drugs (Basel). 2001, Vol 61, Num 12, pp 1765-1776, issn 0012-6667Article

Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571)LA ROSEE, Paul; CORBIN, Amie S; STOFFREGEN, Eric P et al.Cancer research (Baltimore). 2002, Vol 62, Num 24, pp 7149-7153, issn 0008-5472, 5 p.Article

Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid LeukemiaAGARWAL, Anupriya; MACKENZIE, Ryan J; DRUKER, Brian J et al.Clinical cancer research (Print). 2014, Vol 20, Num 8, pp 2092-2103, issn 1078-0432, 12 p.Article

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemiaRADICH, Jerald P; KOPECKY, Kenneth J; TALLMAN, Martin et al.Blood. 2012, Vol 120, Num 19, pp 3898-3905, issn 0006-4971, 8 p.Article

FANCL ubiquitinates β-catenin and enhances its nuclear functionDAO, Kim-Hien T; ROTELLI, Michael D; PETERSEN, Curtis L et al.Blood. 2012, Vol 120, Num 2, pp 323-334, issn 0006-4971, 12 p.Article